Business
Pharmagreen Biotech Provides Commentary on Cannabis Production in North America
Pharmagreen Biotech Provides Commentary on Cannabis Production in North America.
About this update from Pharmagreen Biotech Inc.
[{"type":"text","content":"\nCARSON CITY, NV, Nov. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTCM: PHBI) (“Company”) provided commentary on the burgeoning cannabis production market following its recent legalization October 17, 2018.  Pharmagreen CEO Peter Wojcik provided the following observations in conjunction with how the Company believes its Cannabis Biotech Complex, currently under construction in B.C., Canada, will help solve the infancy stage production issues facing the sector.\n “Recently published news indicates that several leading producers of cannabis have experienced significant production issues, in particular mildew and mold, causing lost crop cycles and the inability to meet Health Canada production quality guidelines. We believe through our proprietary tissue culture process our resulting cannabis starter plantlets for sale to licensed producers, which are healthy, disease fee and pest free, will enable producers to yield high quality crops that meet all production guidelines and contribute positively to maintaining a healthy and regular supply to the public. Utilizing our starter plantlets will also enable growers to maximize their production space by eliminating the need for mothers and clone rooms, thereby driving potential revenue growth, increasing their flowering space and resulting revenue potential. We provide value added services and products to the licensed cannabis industry.” Mr. Wojcik added, “We are also pleased to provide shareholders a scientific update on the Company’s all female plantlets for CBD isolate production as well as the consulting services to be performed at the planned Cannabis Biotech Complex. We will provide cultivation consulting services focused on the development of optimal nutrient feeding schedules for Pharmagreen’s proprietary strains, as well as that of our client’s strains, to greatly reduce the risk of potential nutrient lockup, stunting the plants’ growth and causing a reduction in plant size and yield. For growers seeking additional protection from potential loss of proprietary strains due to plant theft or plant death or for long term off-site genetics preservation in a lab environment, the Biotech Complex will offer the proprietary service of live tissue cultures storage utilizing Pharmagreen̵...